Name of Journal: World Journal of Stem Cells
Manuscript NO: 89703
Manuscript Type: ORIGINAL ARTICLE

Basic Study
Unveiling the role of hypoxia-inducible factor 2alpha in osteoporosis: Implications for bone health

Wang LL et al. HIF-2α inactivation decreases bone mass
Abstract

BACKGROUND
Osteoporosis (OP) has become a major public health problem worldwide. Most OP treatments are based on the inhibition of bone resorption, and it is necessary to identify additional treatments aimed at enhancing osteogenesis. In the bone marrow (BM) niche, bone mesenchymal stem cells (BMSCs) are exposed to a hypoxic environment. Recently, a few studies have demonstrated that hypoxia-inducible factor 2alpha (HIF-2a) is involved in BMSC osteogenic differentiation, but the molecular mechanism involved has not been determined.

AIM
To investigate the effect of HIF-2a on the osteogenic and adipogenic differentiation of BMSCs and the hematopoietic function of hematopoietic stem cells (HSCs) in the BM niche on the progression of OP.

METHODS
Mice with BMSC-specific HIF-2a knockout (Prxl-Cre;Hif-2aβ/β mice) were used for in vivo experiments. Bone quantification was performed on mice of two genotypes with three interventions: Bilateral ovariectomy, semilethal irradiation, and dexamethasone treatment. Moreover, the hematopoietic function of HSCs in the BM niche was compared between the two mouse genotypes. In vitro, the HIF-2a agonist roxadustat and the HIF-2a inhibitor PT2399 were used to investigate the function of HIF-2a in BMSC osteogenic and adipogenic differentiation. Finally, we investigated the effect of HIF-2a on BMSCs via treatment with the mechanistic target of rapamycin (mTOR) agonist MHY1485 and the mTOR inhibitor rapamycin.

RESULTS
The quantitative index determined by microcomputed tomography indicated that the femoral bone density of Prxl-Cre;Hif-2aβ/β mice was lower than that of Hif-2aβ/β mice.
under the three intervention conditions. *In vitro*, Hif-2α flo/flo mouse BMSCs were cultured and treated with the HIF-2α agonist roxadustat, and after 7 d of BMSC adipogenic differentiation, the oil red O staining intensity and mRNA expression levels of adipogenesis-related genes in BMSCs treated with roxadustat were decreased; in addition, after 14 d of osteogenic differentiation, BMSCs treated with roxadustat exhibited increased expression of osteogenesis-related genes. The opposite effects were shown for mouse BMSCs treated with the HIF-2α inhibitor PT2399. The mTOR inhibitor rapamycin was used to confirm that HIF-2α regulated BMSC osteogenic and adipogenic differentiation by inhibiting the mTOR pathway. Consequently, there was no significant difference in the hematopoietic function of HSCs between Prx1-Cre;Hif-2α flo/flo and Hif-2α0/0 mice.

**CONCLUSION**

Our study showed that inhibition of HIF-2α decreases bone mass by inhibiting the osteogenic differentiation and increasing the adipogenic differentiation of BMSCs through inhibition of mTOR signaling in the BM niche.

**Key Words:** Hypoxia-inducible factor-2α; Bone marrow niche; Bone mesenchymal stem cells; Osteoporosis; Osteogenic/adipogenic differentiation; Mechanistic target of rapamycin signaling pathway


**Core Tip:** This manuscript explores the role of hypoxia-inducible factor 2alpha (HIF-2α) in bone mesenchymal stem cell (BMSC) osteogenic differentiation in the bone marrow niche, a role that is still unclear and controversial, *via in vivo and in vitro* experiments. We verified that downregulation of HIF-2α inhibits osteogenesis *in vivo* by generating
mice with BMSC-specific HIF-2α knockout and applying interventions such as bilateral ovariectomy, semilethal irradiation, and treatment with dexamethasone. In vitro, we found that downregulation of HIF-2α can inhibit osteogenesis and increase adipogenesis by suppressing the mechanistic target of rapamycin signaling pathway, which may lead to the identification of drug target genes for the clinical treatment of osteoporosis.

**INTRODUCTION**

Osteoporosis (OP) is a disorder associated with a decrease in bone mineral density (BMD), a low bone mass and increased bone fragility, and it increases the risk of fragility fractures. The economic and social burden of fragility fractures is massive, previously estimated at 37 billion euros per year in 27 European countries alone[1]. OP has become an important public health problem in China. From December 2017 to August 2018, the China Osteoporosis Prevalence Study enrolled a representative sample of 20416 participants aged 20 years or older from mainland China, and the overall prevalence of OP was 20.6% among women aged 40 years or older and 5.0% among men aged 40 years or older. The prevalence of OP among postmenopausal women was 32.1%, and the prevalence of OP among men aged 50 years or older was 6.9%. The prevalence of vertebral fracture was 10.5% among men and 9.7% among women[2]. Therefore, it is important for us to investigate the mechanism of OP.

Bone is a highly dynamic tissue with continuous remodeling at the surface that supports body weight and maintains mineral homeostasis. Bone homeostasis requires coordinated activities between osteoblasts and osteoclasts. Osteoblasts are responsible for the deposition of bone matrix on the bone surface, and osteoclasts are responsible for bone resorption[3]. Age-related (type II) OP is a common and debilitating condition driven in part by the loss of bone marrow (BM) mesenchymal stromal cells and their osteoblast progeny, leading to reduced bone formation. Current pharmacological regimens targeting age-related OP do not directly treat the disease by increasing bone formation but instead use bisphosphonates to reduce bone resorption - a treatment
approach designed for postmenopausal (type-I) OP\textsuperscript{[4]}. It is important to identify an OP treatment focused on increasing bone formation.

Bone mesenchymal stem cells (BMSCs) are multipotent marrow stromal cells. Upon exposure to different extracellular stimuli, different sets of signaling pathways and transcription factors are activated or inhibited in BMSCs, leading to distinct fates of differentiation into cells of different lineages, such as osteoblasts (bone-forming cells), chondrocytes (cartilage cells) and marrow adipocytes (fat cells). The two other major functions of BMSCs include functioning as cellular components of the hematopoietic stem cell (HSC) niche and immunosuppression\textsuperscript{[5]}. In the BM, BMSCs are exposed to a hypoxic environment. Spencer et al\textsuperscript{[6]} performed direct in vivo measurements of local oxygen tension (pO\textsubscript{2}) in the BM of live mice. Using two-photon phosphorescence lifetime microscopy, the authors determined that the absolute pO\textsubscript{2} of the BM was quite low (< 32 mmHg). Cellular adaptation to hypoxia is mediated in part by hypoxia-inducible factors (HIFs). HIFs are composed of two subunits, an O\textsubscript{2}-labile α subunit (HIF-1α, HIF-2α, or HIF-3α) and a constitutively expressed β subunit (HIF-1β, also known as aryl hydrocarbon receptor nuclear translocator)\textsuperscript{[7]}. Tissue-specific deletion of HIF1α, HIF2α, or the HIF-α degradation machinery component proline hydroxylase domain 2 (Phd2) or von Hippel-Lindau (Vhl) results in a variety of skeletal phenotypes that underscore the complexity of skeletal HIF-α signaling during development and disease\textsuperscript{[8]}. Briefly, hypoxia and HIF-α promote skeletal mesenchymal condensation and limb development, promoting chondrogenesis by increasing Sox9 expression and reducing osteogenesis through Runtx2 inhibition\textsuperscript{[9]}. Most of the results showed that HIF-1α represents a potential therapeutic target for preventing osteoclast activation and bone loss in postmenopausal patients\textsuperscript{[10]}. Recently, a few studies have demonstrated that HIF-2α is involved in BMSC osteogenic differentiation, but the molecular mechanism and role of HIF-2α in hematopoietic function in the BM niche have not been determined.

In this study, we generated mice with BMSC-specific HIF-2α knockout (Prx1-Cre;Hif-2α\textsuperscript{−/−} mice) to study the osteogenic/adipogenic differentiation capacity of BMSCs and
the hematopoietic microenvironment of HSCs in order to reveal the influence of HIF-2α regulation in the BM niche on OP, determine the related mechanism, and identify drug target genes that promote bone formation for the clinical treatment of OP.

MATERIALS AND METHODS

Mice
Hif-2αfl/fl mice (008407-Epas1tm1Mcs/J) were purchased from the Jackson Laboratory. Hif-2αfl/fl mice were crossed with Prx-1-Cre transgenic mice (kindly provided by Professor Meng Zhao (Sun Yat-sen University, Guangzhou, China) to produce mice with conditional knockout of HIF-2α in BMSCs (Prx-1-Cre;Hif-2αfl/fl mice). Age- and sex-matched WT littermates (Hif-2αfl/fl) were used as controls. The primers used for genotyping are listed in Table 1. Hif-2αfl/fl and Prx-1-Cre;Hif-2αfl/fl mice were subjected to ovariectomy, dexamethasone (DEX) treatment, or semilethal irradiation. Mice of the same age (6-8 wk), sex, and genotype were randomly grouped for subsequent experiments (the investigators were not blinded). No sex-related differences were observed in the Prx-1-Cre;Hif-2αfl/fl mice. All animals were maintained under specific pathogen-free conditions and fed a standard diet.

Microcomputed tomography
The harvested bones were fixed for 48 h in 4% paraformaldehyde and then dehydrated in 80% ethanol. By using a microcomputed tomography (μCT) 100 scanner (isotropic voxel size of 10 μm, 70 kVp, 200 μA, integration time of 200 ms; Scanco Medical, Switzerland), femora were analyzed as previously described[11]. Determination of the trabecular and cortical bone volume (BV) fractions [BV/total volume (TV)], BMD, thickness (trabecular thickness), trabecular number and trabecular separation was performed using established analysis protocols, and the μCT parameters were reported according to international guidelines.

Ovariectomy-induced OP
For OP induction by ovariectomy, 8-wk-old virgin female mice were anesthetized with 10 µL/g 0.6% pentobarbital sodium, the fur was shaved, and the skin was disinfected with betadine. A dorsal midline incision was made, and the periovarian fat pad was gently grasped to exteriorize the ovary. The fallopian tube was then clamped, and the ovary was removed by cutting above the clamped site. The uterine horn was returned to the abdomen, and the same process was repeated on the other side. After surgery, antibiotic water (250 mL sterile water + 2.5 mL of enrofloxacin) was provided for one week, and the mice were closely monitored until they resumed full activity[12].

**DEX treatment**

Two-month-old Prx1-Cre;Hif-2αβ/β and Hif-2αβ/β male mice were treated with daily intraperitoneal injection of phosphate buffered saline or 20 mg/kg DEX for 28 d[12].

**Semilethal irradiation**

Both Prx1-Cre;Hif-2αβ/β and Hif-2αβ/β male mice received whole-body X-irradiation (4.5 Gy, semilethal dose; Rs2000, Rad Source). After surgery, the mice were provided antibiotic water (250 mL sterile water + 2.5 mL enrofloxacin) for 1 wk[13]. Peripheral blood (PB) was collected from individual mice in heparin-coated capillary tubes to measure white blood cell (WBC) counts on days 0, 7, 14, 21, 28, and 42 after semilethal irradiation.

**5-fluorouracil treatment**

5-fluorouracil (5-FU) was administered intraperitoneally to Prx1-Cre;Hif-2αβ/β and Hif-2αβ/β mice once a week for 2 wk at a dose of 150 mg/kg body weight[14].

**Blood cell counts**

PB was collected from the tail vein and analyzed using a ProCyte Dx Hematology Analyzer (IDEXX).
**BM digestion**

Enzymatic digestion of BM was performed as described previously\(^{[15]}\). Briefly, intact marrow plugs were flushed from the long bones and subjected to two rounds of enzymatic digestion at 37 °C for 20 min each. The digestion buffer contained 3 mg/mL type I collagenase, 4 mg/mL dispase, and 1 U/mL DNase I in HBSS supplemented with calcium and magnesium. The cells were resuspended in staining medium (HBSS + 2% fetal bovine serum) to terminate digestion.

**Fibroblast colony-forming unit assay**

BM cells were collected from the bilateral femora of the mice and subjected to fibroblast colony-forming unit (CFU-F) assays as previously described\(^{[16]}\). Briefly, 10\(^6\) cells were cultured for 7 d. The cells were stained with 0.1% crystal violet, and colony-forming units were counted under a microscope\(^{[13]}\).

**Fluorescence-activated cell sorting analysis**

BMSCs were identified by the expression of PDGFRα\(^{[17]}\) and CD51\(^{[18]}\). For classification of HSCs, long-term HSCs were defined as Lin\(^{-}\)Sca1\(^{+}\)c-KIT\(^{+}\) (LSK) CD34\(^{-}\)FLK2\(^{-}\) cells; short-term HSCs, as LSKCD34\(^{+}\)FLK2 cells; multipotent progenitors, as LSKCD150\(^{-}\)CD48\(^{-}\) cells; and HSCs, as LSKCD150\(^{+}\)CD48\(^{-}\) cells. For classification of hematopoietic progenitor cells (HPCs), common myeloid progenitors were defined as Lin\(^{-}\)c-Kit\(^{+}\)Sca-1\(^{-}\)CD16/32\(^{\text{med}}\)/CD34\(^{+}\) cells; common lymphoid progenitors, as Lin\(^{-}\)c-Kit\(^{\text{low}}\)Sca-1\(^{\text{low}}\)CD127\(^{+}\) cells; and granulocyte-monocyte progenitors, as Lin\(^{-}\)c-Kit\(^{+}\)Sca-1\(^{-}\)CD16/32\(^{\text{high}}\)/CD34\(^{+}\) cells; and megakaryocyte-erythroid progenitors, as Lin\(^{-}\)c-Kit\(^{+}\)Sca-1\(^{-}\)CD16/32\(^{\text{med}}\)/CD34\(^{\text{high}}\) cells.

For cell cycle analysis, BM cells freshly harvested from femora and tibiae were stained with antibodies conjugated to various fluorochromes, fixed and permeabilized with 0.2% Triton X-100, stained with an Alexa Fluor 488-conjugated anti-Ki-67 antibody, and further incubated with DAPI (0.1 mg/mL)\(^{[14]}\).
**In vitro differentiation**

Equal numbers of cultured cells from Hif-2αα/α and Prx1-Cre;Hif-2αα/α mice were replated to ensure that there was no difference in the density of the cells of the different genotypes. On the second day of culture, the medium was replaced with adipogenic (7 d) or osteogenic (7 d or 14 d) differentiation medium. The osteogenic differentiation medium consisted of MEM supplemented with 10 mmol/L β-glycerol phosphate disodium salt, 10 nM DEX (D1756) and 50 μM L-ascorbic acid[19]. Fourteen days later, the percentage of colonies that contained osteoblasts was quantified by alizarin red staining (1%, pH = 4.2; Solarbio). Adipogenic differentiation was induced by the addition of α-MEM containing 10% fetal calf serum, insulin (1 μg/mL; Sigma), 1 μM DEX (Sigma), and 0.5 mmol/L 3-isobutyl-1-methylxanthine (Sigma). The differentiation of adipocytes was monitored by Oil red O staining[11].

**Quantitative real-time polymerase chain reaction**

Total RNA was extracted from cells and tissues according to the Trizol reagent RNA extraction protocol (Magen). cDNA was obtained by reverse transcription of 1 μg of RNA according to the manufacturer's instructions (Takara). Gene expression levels were measured using real-time polymerase chain reaction (RT-PCR) with a CFX96 Touch. The primers used are listed in Table 2. Actin was used as an internal control.

**Western blot analysis**

Total protein was extracted from cells and tissues with radioimmunoprecipitation assay buffer. Equal amounts of extracted proteins were separated via 12.5% sodium-dodecyl sulfate gel electrophoresis and transferred to a polyvinylidene fluoride membrane. After blocking with 5% nonfat milk in Tris-buffered saline with Tween 20 (TBST, pH = 7.6) for 1 h at room temperature, the membranes were incubated with primary antibodies [specific for mechanistic target of rapamycin (mTOR), AKT, and β-actin] overnight at 4 °C and then incubated with secondary antibodies (rabbit, 1:10000) for 1 h.
at room temperature. Western blot images were acquired with a ChemiDoc XRS imaging system (Bio-Rad).

**Statistical analysis**

All the statistical analyses were performed with GraphPad Prism (version 8.0). The statistical significance of differences between two groups was determined using unpaired Student’s t test (two-sided), unless otherwise specified in the figure legends. In all the studies, the data are shown as the mean ± SD values, and statistically significant differences are indicated in the figures; *P < 0.05, **P < 0.01, ***P < 0.001.

**RESULTS**

*Generation of a mouse model with BMSC-specific knockout of HIF-2α*

To assess the physiological function of HIF-2α in early osteoblast lineage cells, we generated HIF-2α CKO mice with Prx1-Cre transgenic mice (Figure 1A), which express Cre recombinase in BMSCs. Briefly, we mated floxed HIF-2α mice with Prx1-Cre transgenic mice to generate Prx1-Cre;Hif-2α<sup>flo/flo</sup> mice, which were mated with Hif-2α<sup>flo/flo</sup> mice to generate Hif-2α<sup>flo/flo</sup> mice, Prx1-Cre;Hif-2α<sup>wt/wt</sup> mice, and Prx1-Cre;Hif-2α<sup>flo/flo</sup> mice. Littermate mice were used in all the experiments. The genotyping primers used are listed in Table 1, and the DNA genotyping results are shown in Figure 1B and C. Mice with the above genotypes were born at normal Mendelian ratios and did not exhibit significant weight or developmental differences (Figure 4A and B). To confirm the deletion of HIF-2α in Prx1-Cre;Hif-2α<sup>flo/flo</sup> BMSCs, the HIF-2α protein expression was analyzed in BMSCs, and HIF-2α was found to be efficiently deleted in most BMSCs from Prx1-Cre;Hif-2α<sup>flo/flo</sup> mice (Figure 1D). Moreover, quantitative RT-PCR analysis of total RNA extracted from BMSCs and from the spleen, muscle, and liver showed that the expression levels of HIF-2α mRNA (Figure 1E) and HIF-2α exon 2 (Figure 1I) were significantly lower in the BMSCs of Prx1-Cre;Hif-2α<sup>flo/flo</sup> mice than in those of Hif-2α<sup>flo/flo</sup> mice, but there were no differences in these levels in the spleen (Figure 1F and J), muscle (Figure 1G and K) or liver (Figure 1H and L) between the two genotypes of
mice. Next, we used μCT and hematoxylin and eosin staining to evaluate the effects of HIF-2α deletion on bone morphometry. μCT analysis revealed that there were no differences in bone mass between Prx1-Cre;Hif-2αβ/β and Hif-2αβ/α mice (Figure 2A and C-F). Hematoxylin and eosin staining[20] also showed that there were no differences in bone mass between Prx1-Cre;Hif-2αβ/β and Hif-2αβ/α mice (Figure 2G-I). Furthermore, as BMSCs are the major source cells for bone formation, we determined the number of BMSCs in Prx1-Cre;Hif-2αβ/β and Hif-2αβ/α mice. Fluorescence-activated cell sorting (FACS) analysis showed that the frequency of BMSCs was significantly reduced in Prx1-Cre;Hif-2αβ/α mice (Figure 2J and K).

**Mice with BMSC-specific HIF-2α knockout exhibited significantly reduced femoral bone density, which exacerbated the occurrence and development of OP in these mice**

As there was a difference in the frequency of BMSCs between Prx1-Cre;Hif-2αβ/β and Hif-2αβ/α mice, we used 3 different interventions to modulate the bone mass in these mice. μCT analysis revealed an osteopenic phenotype in Prx1-Cre;Hif-2αβ/α mice after each of the 3 interventions.

First, 4 wk after bilateral ovariectomy, clinical postmenopausal OP was simulated in female mice. Differences in bone phenotypes between the two genotypes of mice were quantified by μCT. Figure 3A shows the three-dimensional μCT reconstructions of the distal femora of mice of the different genotypes. Quantitative analysis indicated that, compared with those in Hif-2αβ/β mice, the trabecular BV (Figure 3B) and trabecular thickness (Figure 3D) was decreased, the trabecular number (Figure 3C) was decreased, and the trabecular separation (Figure 3F) was increased in Prx1-Cre;Hif-2αβ/β mice. The above results suggest that after bilateral ovariectomy, the bone mass of Prx1-Cre;Hif-2αβ/β mice decreased significantly compared with that of Hif-2αβ/β mice.

Second, semilethal irradiation was used to induce OP in mice of different genotypes. Differences in bone phenotypes between mice of the two genotypes were quantified by μCT. Figure 3G shows the three-dimensional μCT reconstructions of the distal femora of mice of the different genotypes. Analysis of the quantitative indicators suggested that
the trabecular BV (BV/TV, as shown in Figure 3H) and trabecular number (Figure 3I) were decreased and the trabecular separation (Figure 3L) was increased in Prx1-Cre;Hif-2α^fl/fl mice compared with Hif-2α^fl/fl mice and that the trabecular thickness (Figure 3J) was decreased in Prx1-Cre;Hif-2α^fl/fl mice compared to WT mice. Taken together, these results suggest that after semilethal irradiation, the bone mass of Prx1-Cre;Hif-2α^fl/fl mice decreased significantly compared with that of Hif-2α^fl/fl mice.

Mice of the different genotypes were treated with DEX, and after 4 wk, the differences in bone phenotypes between the two genotypes were quantified via μCT. Figure 3M shows the three-dimensional μCT reconstructions of the distal femora of mice of the different genotypes, and analysis of the quantitative indicators indicated a decrease in the trabecular number (Figure 3O) and an increase in the trabecular separation (Figure 3R) in Prx1-Cre;Hif-2α^fl/fl mice compared with Hif-2α^fl/fl mice. Similarly, compared with that in Hif-2α^fl/fl mice, the trabecular BV (BV/TV, as shown in Figure 3N) in Prx1-Cre;Hif-2α^fl/fl mice was decreased. There were no differences in the trabecular thickness (Figure 3P) or BMD (Figure 3Q) between the two genotypes of mice. The above results suggested that, after DEX treatment, the bone mass of Prx1-Cre;Hif-2α^fl/fl mice decreased significantly compared to that of WT mice.

**BMSC-specific knockout of HIF-2α had no significant effect on the hematopoietic function of HSCs or HPCs**

As the above results revealed the difference in bone mass between Prx1-Cre;Hif-2α^fl/fl and Hif-2α^fl/fl mice, the effect of HIF-2α in the BM microenvironment on the hematopoietic functions of HSCs and HPCs was deemed worthy of investigation. Under naive conditions, tail vein blood of Prx1-Cre;Hif-2α^fl/fl and Hif-2α^fl/fl mice was analyzed via a PB test. The results indicated that the concentration of hemoglobin (HGB, as shown in Figure 4J) in Prx1-Cre;Hif-2α^fl/fl mice was 149 g/L, the HGB concentration in Hif-2α^fl/fl mice was 163 g/L, the hematocrit (HCT, as shown in Figure 4K) in Prx1-Cre;Hif-2α^fl/fl mice was 45%, and the HCT in Hif-2α^fl/fl mice was 49.6%, but no significant differences were observed in the RBC (Figure 4l), leukocyte (WBC, as shown
in Figure 4L), neutrophil/monocyte (NEU, as shown in Figure 4N), lymphocyte (LYMPH, as shown in Figure 4O) and platelet (PLT, as shown in Figure 4M) counts between the two genotypes of mice.

Furthermore, we isolated the total nucleated cell (TNC) population from the BM of Prx1-Cre;Hif-2αß/ß and Hif-2αß/ß mice for analysis. First, we analyzed the TNC number (as shown in Figure 4C) and found no significant difference between the two genotypes. Then, we analyzed the total number (Figure 4E) and proportion (Figure 4D) of HSCs in Prx1-Cre;Hif-2αß/ß mice and Hif-2αß/ß mice and found that there were no significant differences. Furthermore, we analyzed the cell cycle distribution of HSCs from Prx1-Cre;Hif-2αß/ß mice and from Hif-2αß/ß mice and found no significant differences (Figure 4F). Moreover, we analyzed the total number (Figure 4H) and proportion (Figure 4G) of HPCs in Prx1-Cre;Hif-2αß/ß mice and Hif-2αß/ß mice, and the results did not reveal significant differences. In general, the BMSC population in Prx1-Cre;Hif-2αß/ß mice was significantly reduced under naive conditions, but there were no significant differences in the BM HSC and HPC populations in Prx1-Cre;Hif-2αß/ß mice compared with Hif-2αß/ß mice; thus, genetic deletion of HIF-2α in BMSCs had no effect on the hematopoietic microenvironment.

Under naive conditions, there were no significant differences in the hematopoietic phenotype between Prx1-Cre;Hif-2αß/ß mice and Hif-2αß/ß mice. To further clarify the difference in the hematopoietic microenvironment between Prx1-Cre;Hif-2αß/ß mice and Hif-2αß/ß mice, mice received two different interventions (including semilethal irradiation and 5-FU injection), and hematopoietic differences were evaluated. First, we observed hematopoietic changes after BM injury induced by semilethal irradiation. First, we collected PB from Prx1-Cre;Hif-2αß/ß mice and Hif-2αß/ß mice, and blood analysis indicated that beginning at the third week after irradiation, the recovery of WBCs (Figure 5A) and NEUs (Figure 5B) in Prx1-Cre;Hif-2αß/ß mice was significantly slower than that in Hif-2αß/ß mice. However, there were no statistically significant differences in HGB concentration (Figure 5C) or PLT count (Figure 5D) between Prx1-Cre;Hif-2αß/ß mice and Hif-2αß/ß mice.
Moreover, the HSCs and HPCs of Hif-2αβ/β and Prx1-Cre;Hif-2αβ/β mice were analyzed during the second week after semilethal irradiation. The results suggested that there was no significant difference in the TNC number (Figure 5E). Then, we analyzed the total number (Figure 5G) and proportion (Figure 5F) of HSCs and HPCs (Figure 5H and I) between the two genotypes of mice. There were no significant differences.

We subsequently administered an intervention that caused BM injury in mice, i.e., intraperitoneal injection of 5-FU, and then analyzed HSCs and HPCs in the BM of Prx1-Cre;Hif-2αβ/β mice and Hif-2αβ/β mice. The results still indicated that there was no significant difference in the number of TNCs in Prx1-Cre;Hif-2αβ/β mice compared with Hif-2αβ/β mice (Figure 5J). We subsequently analyzed the total number and proportion of HSCs and HPCs in the two genotypes of mice, and we found that the total number of HSCs (as shown in Figure 5L), the proportion of HSCs (as shown in Figure 5K), the total number of HPCs (as shown in Figure 5N) and the proportion of HPCs (as shown in Figure 5M) in Prx1-Cre;Hif-2αβ/β mice did not significantly differ from those in Hif-2αβ/β mice. Combined with the results of analysis of the hematopoietic phenotypes of the two mouse genotypes after irradiation, these results suggested that the hematopoietic recovery ability of Prx1-Cre;Hif-2αβ/β mice after BM injury was not significantly different from that of Hif-2αβ/β mice.

**HIF-2α promoted the osteogenic differentiation and inhibited the adipogenic differentiation of BMSCs in vitro**

BMSCs from Prx1-Cre;Hif-2αβ/β mice and Hif-2αβ/β mice were isolated to evaluate the fibroblast colony formation ability of the BMSCs and determine their proliferation ability. There was no difference in the CFU-F between Prx1-Cre;Hif-2αβ/β and Hif-2αβ/β mice. Representative images of CFU-Fs in Prx1-Cre;Hif-2αβ/β and Hif-2αβ/β mice are shown in Figure 6A. The quantification of the CFU-Fs formed by the BMSCs is shown in Figure 6B.

Because of the long duration of cell differentiation, there were no differences in the percentages of BMSCs isolated from Prx1-Cre;Hif-2αβ/β and Hif-2αβ/β mice before
compared with after the interventions (bilateral ovariectomy, sublethal irradiation, or DEX treatment); therefore, in the remaining studies, we used BMSCs from naive mice. Hif-2αΔ/Δ mouse BMSCs were cultured and divided into the roxadustat and control groups according to whether they were treated with the HIF-2α agonist roxadustat. After 7 d of adipogenic differentiation, the adipogenic capacity of the roxadustat group was decreased. Oil red O staining indicated that the number of lipid droplets in the BMSCs of the roxadustat group was lower than that in the control group (Figure 6D), and quantification of oil red O staining indicated that lipid droplet formation was reduced in the BMSCs of the roxadustat group (Figure 6C). qPCR analysis revealed that roxadustat treatment significantly downregulated adipogenesis-related genes, such as Lpl (Figure 6E), adiponectin (Figure 6F) and CEBPa (Figure 6G), in BMSCs. These results suggest that activation of HIF-2α can reduce the adipogenic differentiation capacity of BMSCs.

After 14 d of osteogenic differentiation, the osteogenic differentiation capacity of the BMSCs in the roxadustat group was increased. Alizarin red staining indicated that the osteogenic differentiation capacity of the roxadustat group was increased compared with that of the control group (Figure 6I). Similarly, compared with those in the control group, the mRNA levels of osteogenesis-related genes, such as OCN (Figure 6H), Runx2 (Figure 6J) and Col1α1 (Figure 6K), were significantly increased in the roxadustat group. These results suggest that activation of HIF-2α can lead to an increased osteogenic differentiation capacity of BMSCs.

**HIF-2α regulated adipogenesis and osteogenesis by inhibiting the mTOR pathway**

To further investigate whether HIF-2α affects the osteogenic/adipogenic differentiation of BMSCs through the mTOR signaling pathway, we extracted protein and mRNA from BMSCs in the roxadustat group and the control group after adipogenic differentiation. The results suggested that, during the process of adipogenic differentiation, at the translational level, the levels of the key proteins of the mTOR signaling pathway - the p-mTOR protein and the downstream proteins p-PI3K and p-AKT (as shown in Figure
were significantly reduced in the roxadustat group (Figure 6L). Moreover, the mTOR activator MHY1485 was used to verify whether it could rescue the decreased adipogenic differentiation capacity of BMSCs. The results proved that the mTOR activator MHY1485 increased adipogenic capacity of BMSCs (Figure 7A and B) and the mRNA levels of the mTOR signaling pathway components (Figure 7C). Moreover, the protein levels of the mTOR signaling pathway components were increased (Figure 6L and M).

On the other hand, we used the HIF-2α inhibitor PT2399 and the mTOR inhibitor rapamycin to confirm that HIF-2α regulates adipogenesis by inhibiting the mTOR pathway. We divided cultured BMSCs into three different groups: The control group, the PT2399 group, and the PT2399 + rapamycin group. The results showed that the PT2399 + rapamycin treatment group exhibited a decreased adipogenic differentiation capacity, which was increased in the PT2399 group. Oil red O staining and quantitative analysis indicated that lipid droplet formation was increased in the PT2399-treated BMSCs (Figure 7F), and that after BMSCs were treated with PT2399 and rapamycin, their adipogenic differentiation capacity decreased. At the transcriptional level, the expression levels of genes related to adipogenesis in BMSCs were significantly upregulated in the PT2399 group and downregulated in the PT2399 + rapamycin group (Figure 7D). Similarly, the expression of key mRNAs in the mTOR signaling pathway was significantly decreased in the PT2399 + rapamycin group compared to the PT2399 group (Figure 7E). Then, we extracted protein from BMSCs in the PT2399 group and the PT2399 + rapamycin group after adipogenic differentiation. The results suggested that, during the process of adipogenic differentiation, the levels of the mTOR and p-mTOR proteins and the downstream proteins PI3K, p-PI3K and p-AKT (as shown in Figure 7H) were significantly increased in the PT2399 group but decreased in the PT2399 + rapamycin group (Figure 7G).

Furthermore, we verified the relevant results regarding the osteogenic differentiation of BMSCs using the HIF-2α inhibitor PT2399 and the mTOR inhibitor rapamycin. Similarly, we divided the cultured BMSCs into three different groups: The control
group, the PT2399 group, and the PT2399 + rapamycin group. The results showed that rapamycin rescued the decreased osteogenic differentiation ability of the PT2399 group. Alizarin red staining was used to quantify the osteogenic differentiation capacity of the cells, and the results indicated that the osteogenic differentiation capacity was decreased in the PT2399 group (Figure 8A); moreover, for the in BMSCs treated with PT2399 and rapamycin, the osteogenic differentiation capacity was increased. At the transcriptional level, the expression of genes related to osteogenesis in BMSCs, such as OCN (Figure 8B), RUNX2 (Figure 8C) and Col1α1 (Figure 8D), was significantly downregulated in the PT2399 group and upregulated in the PT2399 + rapamycin group. Then, after osteogenic differentiation, we extracted protein from the BMSCs in the PT2399 group and the PT2399 + rapamycin group. The results suggested that, during the process of osteogenic differentiation, the levels of the mTOR and p-mTOR proteins and the downstream proteins PI3K, p-PI3K, p-AKT and AKT (as shown in Figure 8E) were significantly increased in the PT2399 group but decreased in the PT2399 + rapamycin group (Figure 8F).

DISCUSSION
We successfully generated mice with BMSC-specific HIF-2α knockout, which were used for our subsequent studies. Notably, during the process of generating the Prxl-Cre;Hif-2αfl/fl mice, we found that female mice harboring the Prxl-Cre gene could not be mated. Upon further investigation, we found that the birth rate of the mice was very low and that the stillbirth rate was high. We have not further clarified and studied the mechanism of this phenomenon, but upon observing this phenomenon, we avoided using females with the prxl-Cre transgene as for breeding; therefore, we expanded the mouse population by mating female Hif-2αfl/fl mice with male Prxl-Cre;Hif-2αfl/fl mice. This phenomenon has not been explained by the relevant literature in other studies and could be investigated in our future research.

Many studies have explored the role of HIF-1α in bone homeostasis and have shown that HIF-1α can promote osteogenesis. It was reported that mice lacking Hif-1α
exhibited a significant reduction in trabecular BV, a reduced bone formation rate, and altered cortical bone architecture. In contrast, mice lacking HIF-2α had only a modest decrease in trabecular BV\textsuperscript{[21]}. It has also been suggested that HIF-1α stabilization in osteoblast precursors of postnatal mice markedly increases the osteoblast number and bone mass\textsuperscript{[22]}. Recently, several studies have demonstrated that HIF-2α is involved in BMSC osteogenic differentiation. However, the molecular mechanism and role of HIF-2α in hematopoietic function in the BM niche have not been determined. Although the two α subunits are structurally similar and recognize the same DNA elements, the target genes regulated by HIF-1α and HIF-2α are not identical. Cheng et al\textsuperscript{[23]} generated conditional Phd2 knockout (cKO) mice from osteoblast lineage cells by crossing floxed Phd2 mice with a Col1α2-i Cre line to investigate the function of Phd2 in vivo. The cKO mice developed short stature and experienced premature death at 12 to 14 wk of age. Compared to WT mice, cKO mice had a reduced bone mineral content, bone area, and BMD in the femora and tibiae but not in the vertebrae. The TV, BV and BV fraction (BV/TV) of femoral trabeculae in cKO mice were significantly decreased\textsuperscript{[24]}. A recent study by Lee et al\textsuperscript{[24]} suggested that HIF-2α deficiency promoted osteoblast differentiation and inhibited osteoclast differentiation by increasing bone mass. Merceron et al\textsuperscript{[25]} demonstrated that HIF-2α is an inhibitor of osteoblast formation and increased bone mass. Guo et al\textsuperscript{[26]} conditionally knocked out HIF-2α in leptin receptor-expressing cells and their progeny in mice and found that radiation therapy in littermate control mice reduced bone mass, but HIF-2α conditional knockout mice maintained a bone mass comparable to that of nonirradiated control animals.

Taken together, our findings in this study support the role of HIF-2α in promoting osteogenesis, especially in combination with interventions such as bilateral ovariectomy, semilethal irradiation, and DEX treatment. Moreover, the Prx1-Cre;Hif-2α\textsuperscript{fl/fl} phenotype did not significantly differ in terms of BMD in mice under the naive condition, but the BMD in mice subjected to the various stimulation interventions was indicative of a significant decrease in osteogenesis in Prx1-Cre;Hif-2α\textsuperscript{fl/fl} mice. We hypothesized that the concentration of HIF-2α in the BM of mice under stress
stimulation was elevated, leading to an alteration in BMD in these mice. Our results are consistent with those of previous studies. Shomento et al.[21] used Osteocalcin-Cre mice and HIF-2α Flox mice to generate mice with osteoblast-specific HIF-2α knockout, and the results suggested that KO mice had reduced BMD. Wu et al.[27] selected osx-cre-labeled osteoblasts and PHD mutant mice to generate mice with osteoblast-specific PHD knockout, which exhibited increased BMD. Wang et al.[28] overexpressed HIFα in osteoblasts of mice by selective deletion of the Vhl, resulting in increased BMD.

Taken together, our results suggest that HIF-2α deletion in the BM microenvironment does not significantly affect HSC or HPC function in mice. These results indicate that the HIF-2α gene in the BM microenvironment does not affect the stromal niche of HSCs, only bone formation. Our results are consistent with those of previous studies. Wu et al.[27] selected Osx-cre-labeled osteoblasts and PHD mutant mice to generate mice with osteoblast-specific PHD knockout (KO). The KO mice exhibited increased BMD without disruption of hematopoietic homeostasis[27]. However, notably, although the deletion of HIF-2α had no significant effect on HSC function, PB analysis revealed that the hemoglobin content and hematocrit value were significantly lower in Prx1-Cre;Hif-2αfl/fl mice than in WT mice, suggesting that other mechanisms may lead to the decreased hemoglobin content observed in Prx1-Cre;Hif-2αfl/fl mice. Rankin et al.[29] reported that pharmacological or genetic inhibition of prolyl hydroxylases 1/2/3 in osteoprogenitors elevated EPO expression in bone and increased the hematocrit value, an effect believed to be caused by increased EPO expression and modulation of erythropoiesis in osteoblasts. Our results are consistent with the above results. Therefore, to further study the causes of the decreased hemoglobin content in Prx1-Cre;Hif-2αfl/fl mice observed in this study, further studies can be carried out focusing on EPO.

Recently, accumulating evidence has highlighted the role of mTOR signaling in regulating bone homeostasis, which provides insight into the pathogenesis of OP. It is widely believed that the inhibition of mTOR signaling can promote osteoblastic differentiation, but this remains a controversial issue[30]. Rapamycin is an inhibitor of
mTOR signaling, and a high-throughput screening assay showed that rapamycin can promote osteoblastic differentiation-treatment of osteoblast precursors with rapamycin alone or in combination with bone morphogenetic protein (BMP)-2 increased the levels of the phospho-Smad 1/5/8 proteins and the transcription of Runx-2, Osx and Smad-7, consistent with a role in promoting osteoblastic differentiation[31]. Moreover, rapamycin effectively stimulates the osteoblastic differentiation of human embryonic stem cells by inhibiting rapamycin-sensitive mTOR signaling and promoting BMP/Smad signaling[32]. Similarly, blockade of mTOR signaling by osteoblast-specific knockout or rapamycin treatment rescues the osteopenia phenotype in fibrillin-1-deficient mice by augmenting the osteogenic differentiation and inhibiting the adipogenic differentiation of BMSCs[33]. These findings are consistent with the above results, suggesting that the activation of HIF-2α in BMSCs inhibits the mTOR signaling pathway, resulting in a reduction in the adipogenic differentiation and an increase in the osteogenic differentiation of BMSCs. Therefore, we believe that HIF-2α inhibits adipogenic differentiation and promotes osteogenesis by inhibiting the mTOR signaling pathway.

Under physiological conditions, HIF-2α is hydroxylated by the PHD protein, leading to Vhl-dependent ubiquitination and protease-dependent degradation[34]. Therefore, the PHD inhibitor roxadustat (FG-4592) activates HIF-2α by increasing HIF-2α stability[35]. The drug is currently on the market in China and is approved for the treatment of renal anemia. In addition, several randomized phase II and III trials have shown that roxadustat significantly reduces plasma total cholesterol levels in patients with chronic kidney disease[36-38]. Moreover, roxadustat has potential use as an antiatherosclerotic treatment. Several studies have shown that roxadustat has an inhibitory effect on obesity-induced atherosclerosis, which depends primarily on the regulation of HIF-2α and ceramide metabolism in adipocytes[39]. In addition to its use for treating CKD-related anemia, roxadustat is potentially useful for the treatment of carcinoma, neurological diseases, ocular diseases, tissue injuries, and obesity[40]. However, studies on roxadustat and osteogenesis are rare. Roxadustat has been suggested to promote fracture repair in vivo by increasing the number of BMSCs and promoting
chondrogenesis. *In vitro*, roxadustat significantly improved BMSC proliferation and migration by increasing the concentrations of intracellular calcium ions and NO and simultaneously decreasing the level of reactive oxygen species[^41]. Hulley *et al.*[^42] suggested that roxadustat could inhibit osteoclast activity and subsequent bone resorption after coculture with osteoblasts. Our *in vitro* experiments revealed that roxadustat could promote the osteogenic differentiation of BMSCs and suggested that roxadustat might have a therapeutic effect on promoting osteogenesis in the context of OP. More studies could be carried out to verify the above speculation.

This study has several limitations. We have not verified the effect of HIF-2α on osteoclasts. Since bone homeostasis is a balance between osteoblast and osteoclast activity, the relationship between osteogenesis and osteoclasia should be assessed while observing the phenotype of bone, which is also the focus of our next study.

**CONCLUSION**

In conclusion, through *in vivo* and *in vitro* experiments, we verified that HIF-2α promoted the osteogenic differentiation and inhibited the adipogenic differentiation of BMSCs by inhibiting the mTOR signaling pathway. Moreover, HIF-2α had no effect on the number or function of HSCs or HPCs in the BM microenvironment. *In vivo* experiments showed that OP in Prx1-Cre;Hif-2α0/α mice was aggravated by bilateral ovariectomy, sublethal irradiation, and DEX treatment. Through *in vitro* experiments, it was confirmed that HIF-2α can inhibit the mTOR signaling pathway, leading to multiple factors, such as the promotion of BMSC osteogenic differentiation, inhibition of BMSC adipogenic differentiation, inhibition of erythropoiesis, and promotion of the anti-injury function of WBCs to regulate the BM niche, thus participating in the occurrence and progression of OP.

**ARTICLE HIGHLIGHTS**

*Research background*
Recently, several studies have demonstrated that hypoxia-inducible factor 2alpha (HIF-2α) is involved in bone mesenchymal stem cell (BMSC) osteogenic differentiation. However, the molecular mechanism involved remains unclear.

**Research motivation**
An exploration of osteoporosis (OP) treatments aimed at increasing bone formation is needed.

**Research objectives**
Research on the effects of HIF-2α on the osteogenic and adipogenic differentiation of BMSCs and hematopoietic function in the bone marrow niche.

**Research methods**
*In vivo*, we generated mice with BMSC-specific HIF-2α knockout and induced OP in these mice *via* three interventions: Bilateral ovariectomy, semilethal irradiation, and treatment with dexamethasone.

**Research results**
*In vivo*, the bone mass of KO mice was decreased compared with that of WT mice. *In vitro*, downregulation of HIF-2α inhibited osteogenesis and increased adipogenesis by suppressing the mechanistic target of rapamycin (mTOR) signaling pathway.

**Research conclusions**
In conclusion, through *in vivo* and *in vitro* experiments, we verified that inhibition of HIF-2α can decrease the osteogenic differentiation and increase the adipogenic differentiation of BMSCs by inhibiting the mTOR signaling pathway.

**Research perspectives**
In future research, as many patients with chronic kidney disease also have OP, we will verify whether the HIF-2α agonist roxadustat can successfully treat mice with OP induced via ovariectomy.
<table>
<thead>
<tr>
<th>Primary Sources</th>
<th>Similarity Index</th>
</tr>
</thead>
<tbody>
<tr>
<td>stemcellsjournals.onlinelibrary.wiley.com</td>
<td>62 words — 1%</td>
</tr>
<tr>
<td><a href="http://www.hcplive.com">www.hcplive.com</a></td>
<td>49 words — 1%</td>
</tr>
<tr>
<td>Kyoung Eun Lee, M Celeste Simon. &quot;From stem cells to cancer stem cells: HIF takes the stage&quot;, Current Opinion in Cell Biology, 2012</td>
<td>47 words — 1%</td>
</tr>
<tr>
<td><a href="http://www.nature.com">www.nature.com</a></td>
<td>45 words — 1%</td>
</tr>
<tr>
<td><a href="http://www.science.gov">www.science.gov</a></td>
<td>42 words — 1%</td>
</tr>
<tr>
<td>Gengyang Shen, Hui Ren, Ting Qiu, Zhida Zhang et al. &quot;Mammalian target of rapamycin as a therapeutic target in osteoporosis&quot;, Journal of Cellular Physiology, 2018</td>
<td>41 words — 1%</td>
</tr>
<tr>
<td>link.springer.com</td>
<td>40 words — 1%</td>
</tr>
<tr>
<td>coek.info</td>
<td>38 words — 1%</td>
</tr>
<tr>
<td></td>
<td>Source</td>
</tr>
<tr>
<td>---</td>
<td>---------------------------------</td>
</tr>
<tr>
<td>9</td>
<td>pubmed.ncbi.nlm.nih.gov</td>
</tr>
<tr>
<td>10</td>
<td><a href="http://www.researchgate.net">www.researchgate.net</a></td>
</tr>
<tr>
<td>11</td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>onlinelibrary.wiley.com</td>
</tr>
</tbody>
</table>

Elena Sabini, Lorenzo Arboit, Mohd Parvez Khan, Giulia Lanzolla, Ernestina Schipani. "Oxidative phosphorylation in bone cells", Bone Reports, 2023

jamanetwork.com

Internet